178 related articles for article (PubMed ID: 38251688)
1. CD8
Lee SY; Lee DH; Sun W; Cervantes-Contreras F; Basom RS; Wu F; Liu S; Rai R; Mirzaei HR; O'Steen S; Green DJ; Shadman M; Till BG
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38251688
[TBL] [Abstract][Full Text] [Related]
2. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
3. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Generation of CAR T Cells Selectively in Human CD4
Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
[TBL] [Abstract][Full Text] [Related]
5. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
6.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
8. NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
Wilkens AB; Fulton EC; Pont MJ; Cole GO; Leung I; Stull SM; Hart MR; Bernstein ID; Furlan SN; Riddell SR
Blood; 2022 Nov; 140(21):2261-2275. PubMed ID: 35605191
[TBL] [Abstract][Full Text] [Related]
9. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
10. CD8
Whittington KB; Prislovsky A; Beaty J; Albritton L; Radic M; Rosloniec EF
J Immunol; 2022 Jan; 208(1):16-26. PubMed ID: 34819392
[TBL] [Abstract][Full Text] [Related]
11. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
12. HIV-Resistant and HIV-Specific CAR-Modified CD4
Maldini CR; Gayout K; Leibman RS; Dopkin DL; Mills JP; Shan X; Glover JA; Riley JL
Mol Ther; 2020 Jul; 28(7):1585-1599. PubMed ID: 32454027
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
14. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
Elavia N; Panch SR; McManus A; Bikkani T; Szymanski J; Highfill SL; Jin P; Brudno J; Kochenderfer J; Stroncek DF
Transfusion; 2019 May; 59(5):1755-1764. PubMed ID: 30973976
[TBL] [Abstract][Full Text] [Related]
15. The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
Galli E; Bellesi S; Pansini I; Di Cesare G; Iacovelli C; Malafronte R; Maiolo E; Chiusolo P; Sica S; Sorà F; Hohaus S
Br J Haematol; 2023 Nov; 203(4):564-570. PubMed ID: 37789569
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
Sommermeyer D; Hudecek M; Kosasih PL; Gogishvili T; Maloney DG; Turtle CJ; Riddell SR
Leukemia; 2016 Feb; 30(2):492-500. PubMed ID: 26369987
[TBL] [Abstract][Full Text] [Related]
17. The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome.
Foskolou IP; Barbieri L; Vernet A; Bargiela D; Cunha PP; Velica P; Suh E; Pietsch S; Matuleviciute R; Rundqvist H; McIntyre D; Smith KGC; Johnson RS
Blood Adv; 2020 Sep; 4(18):4483-4493. PubMed ID: 32941648
[TBL] [Abstract][Full Text] [Related]
18. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
19. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
